DeepSyte™
Bill FeedAll repsScoreboardsPrimariesProAboutSign inGet started
DeepSyte™™

A nonpartisan civic accountability tool. We match federal legislation to your stated values — without partisan bias.

Learn

  • About
  • About the name
  • Methodology
  • Glossary

Legal

  • Privacy
  • Terms of Service
  • Refund Policy
  • Contact

Sources

Bill data from Congress.gov. Summaries from the Congressional Research Service where available.

Follow

  • Bluesky — @deepsyte.app
  • X — @deepsyteapp
All content is for informational purposes only. Always verify against primary sources.
Back to bill feed
118-hr-3794Introduced
Sign in to get alerts

FLASH Act of 2023

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Get started freeTake the values quiz

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary
Fast-track Logistics for Acquiring Supplies in a Hurry Act of 2023 or the FLASH Act of 2023 This bill expands federal contracting and other authorities to support the development and acquisition of products and supplies that are necessary for national public health and health security. Specifically, the Department of Health and Human Services (HHS) may use noncompetitive procedures to procure medical countermeasures (e.g., vaccines), chemical materials and reagents, manufacturing supplies, and similar items that are needed to develop products for national public health and health security. Additionally, HHS may acquire, subject to dollar limits and other conditions, innovative commercial products and services by soliciting proposals and selecting proposals through peer review. Further, the bill expands the activities of the Biomedical Advanced Research and Development Authority (BARDA) to include supporting the design and development of prototypes for products to diagnose, mitigate, prevent, treat, or otherwise respond to biological, chemical, radiological, or nuclear threats, including pandemics or epidemics. If BARDA enters an initial transaction to design or develop such a test or prototype using competitive procedures, BARDA may use noncompetitive procedures for a follow-on transaction to produce the test or prototype.
Read full bill text

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

Bill details

Congress
118
Bill type
hr
Introduced
June 5, 2023
Sponsor
Not yet available
Last action
June 22, 2023— Sponsor introductory remarks on measure. (CR H3077)

How your representatives voted

Sign in to see how your representatives voted on this bill.